These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 22870329)
1. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. Madireddi S; Schabowsky RH; Srivastava AK; Sharma RK; Yolcu ES; Shirwan H PLoS One; 2012; 7(8):e42459. PubMed ID: 22870329 [TBL] [Abstract][Full Text] [Related]
2. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. Elpek KG; Yolcu ES; Franke DD; Lacelle C; Schabowsky RH; Shirwan H J Immunol; 2007 Dec; 179(11):7295-304. PubMed ID: 18025172 [TBL] [Abstract][Full Text] [Related]
3. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells. Zhao Y; Croft M Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570 [TBL] [Abstract][Full Text] [Related]
4. 4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression. Barsoumian HB; Yolcu ES; Shirwan H PLoS One; 2016; 11(4):e0153088. PubMed ID: 27049955 [TBL] [Abstract][Full Text] [Related]
5. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. Wen T; Bukczynski J; Watts TH J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439 [TBL] [Abstract][Full Text] [Related]
6. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4 Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845 [TBL] [Abstract][Full Text] [Related]
7. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4 Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367 [TBL] [Abstract][Full Text] [Related]
9. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348 [TBL] [Abstract][Full Text] [Related]
10. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Srivastava AK; Dinc G; Sharma RK; Yolcu ES; Zhao H; Shirwan H Cancer Res; 2014 Nov; 74(22):6441-51. PubMed ID: 25252915 [TBL] [Abstract][Full Text] [Related]
11. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Smith SE; Hoelzinger DB; Dominguez AL; Van Snick J; Lustgarten J Cancer Immunol Immunother; 2011 Dec; 60(12):1775-87. PubMed ID: 21789593 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of cancer with 4-1BB. Vinay DS; Kwon BS Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596 [TBL] [Abstract][Full Text] [Related]
14. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. Kumar P; Bhattacharya P; Prabhakar BS J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217 [TBL] [Abstract][Full Text] [Related]
15. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920 [TBL] [Abstract][Full Text] [Related]
16. Expression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration. Kim YM; Kim HK; Kim HJ; Lee HW; Ju SA; Choi BK; Kwon BS; Kim BS; Kim JB; Lim YT; Yoon S Exp Mol Med; 2009 Dec; 41(12):896-911. PubMed ID: 19745604 [TBL] [Abstract][Full Text] [Related]
19. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Sharma RK; Schabowsky RH; Srivastava AK; Elpek KG; Madireddi S; Zhao H; Zhong Z; Miller RW; Macleod KJ; Yolcu ES; Shirwan H Cancer Res; 2010 May; 70(10):3945-54. PubMed ID: 20406989 [TBL] [Abstract][Full Text] [Related]
20. 4-1BB ligand signaling to T cells limits T cell activation. Eun SY; Lee SW; Xu Y; Croft M J Immunol; 2015 Jan; 194(1):134-41. PubMed ID: 25404362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]